1. Home
  2. ALKT vs IMCR Comparison

ALKT vs IMCR Comparison

Compare ALKT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

HOLD

Current Price

$16.69

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$29.09

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKT
IMCR
Founded
2007
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.5B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
ALKT
IMCR
Price
$16.69
$29.09
Analyst Decision
Buy
Buy
Analyst Count
7
10
Target Price
$28.57
$66.33
AVG Volume (30 Days)
1.7M
279.7K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.39
EPS
N/A
0.25
Revenue
$152,159,000.00
$249,428,000.00
Revenue This Year
$21.85
$14.57
Revenue Next Year
$16.90
$8.21
P/E Ratio
N/A
$119.48
Revenue Growth
35.68
43.05
52 Week Low
$14.11
$27.56
52 Week High
$31.18
$40.71

Technical Indicators

Market Signals
Indicator
ALKT
IMCR
Relative Strength Index (RSI) 48.56 47.22
Support Level $15.16 $28.90
Resistance Level $17.81 $31.56
Average True Range (ATR) 0.79 1.16
MACD -0.01 0.12
Stochastic Oscillator 27.85 33.79

Price Performance

Historical Comparison
ALKT
IMCR

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: